title: Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.
abstract: Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.
authors: Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain.
authors: Roberto
authors: R
authors: Gallego-Pinazo
authors: Rosa
authors: R
authors: Dolz-Marco
authors: Cristina
authors: C
authors: Marín-Lambíes
authors: Manuel
authors: M
authors: Díaz-Llopis
keywords: VEGF; antiangiogenic therapy; macular edema; ranibizumab; retinal vein occlusion
references: Eye (Lond). 2011 Jun;25(6):661-72
references: 21455242
references: Ophthalmology. 2011 Oct;118(10):2041-9
references: 21715011
references: Compr Ophthalmol Update. 2006 Nov-Dec;7(6):265-76
references: 17244442
references: Invest Ophthalmol Vis Sci. 2011 May 09;52(6):3046-50
references: 21051706
references: Ophthalmology. 2008 Oct;115(10):e47-54
references: 18708258
references: Invest Ophthalmol Vis Sci. 2000 Mar;41(3):877-9
references: 10711707
references: Mol Ther. 2008 Apr;16(4):791-9
references: 18362932
references: Ophthalmology. 2011 Aug;118(8):1594-602
references: 21684606
references: Ophthalmology. 2010 Dec;117(12):2387-2394.e1-5
references: 20630595
references: Ophthalmology. 2010 Jun;117(6):1102-1112.e1
references: 20398941
references: Prog Retin Eye Res. 2005 Jul;24(4):493-519
references: 15845346
references: N Engl J Med. 1994 Dec 1;331(22):1480-7
references: 7526212
references: Arch Ophthalmol. 2008 Apr;126(4):513-8
references: 18413521
references: Ophthalmology. 1998 Mar;105(3):412-6
references: 9499769
references: Acta Ophthalmol. 2012 Feb;90(1):e25-30
references: 21958440
references: Ophthalmology. 2010 Jun;117(6):1124-1133.e1
references: 20381871
references: Br J Ophthalmol. 2010 Sep;94(9):1215-8
references: 20538658
references: Atherosclerosis. 2011 Apr;215(2):331-8
references: 21324460
references: Am J Ophthalmol. 2009 Feb;147(2):298-306
references: 18929354
references: Br J Ophthalmol. 1984 Mar;68(3):196-8
references: 6365157
references: Ophthalmology. 2011 Dec;118(12):2453-60
references: 21764136
references: Trans Am Ophthalmol Soc. 1981;79:307-34
references: 7200671
references: Cancer Res. 1990 Mar 15;50(6):1774-8
references: 2155059
references: Arch Ophthalmol. 2009 Sep;127(9):1101-14
references: 19752419
references: Am J Ophthalmol. 2005 Aug;140(2):256-61
references: 16086947
references: Am J Ophthalmol. 1992 Jan 15;113(1):36-8
references: 1728144
references: Ophthalmology. 1995 Oct;102(10):1425-33
references: 9097788
references: Retina. 2011 May;31(5):821-8
references: 21317833
references: Am J Ophthalmol. 2010 Sep;150(3):310-4
references: 20591399
references: Retina. 2011 Jun;31(6):1060-7
references: 21283055